Fresh Recalls

FDAClass II · Drug · Recall D-0521-2026 · Recalled April 29, 2026

Claravis (isotretinoin capsule recall — Teva Pharmaceuticals USA, Inc

Agency report date: April 29, 2026.

1. Compare your item

This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.

Product named
Claravis (isotretinoin capsule
Company / brand
Teva Pharmaceuticals USA
Lot / serial / date codes
Lots#: 100067507, 100067508, Exp 07/31/2026
Distribution
Nationwide in the USA, Puerto Rico and Virgin Islands
Agency product description and boundaries

Claravis (isotretinoin capsule, USP), 10 mg, Packaged as a) 100-count carton, NDC 0555-1054-56, with 10x10 blister packs NDC 0555-1054-60; b) 30-count carton, NDC 0555-1054-86, with 3X10 blister pack NDC 0555-1054-60; Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.

Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.

If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.

2. Agency hazard and consumer action

FDA reports: Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin

No consumer remedy instructions are supplied in this record. Check the official notice and listed company contact for the agency’s current instructions.

Class II: may cause temporary or medically reversible health consequences.

Affected product: Claravis (isotretinoin capsule recall status

3. Open the official notice or contact

Official recall ID
D-0521-2026
Brand
All Teva Pharmaceuticals USA recalls
Classification
Class II
Units affected
5,101 cartons
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Affected products

Companies & origin

Recalling firm location
Parsippany, NJ, United States
Firm address
400 Interpace Pkwy Bldg A, N/A, 07054-1120

Identifying details (verbatim from the notice)

Product codes / lots
Lots#: 100067507, 100067508, Exp 07/31/2026
Distribution
Nationwide in the USA, Puerto Rico and Virgin Islands
Firm notified the public via
Letter
FDA event ID
98730
Recall initiated
April 6, 2026
FDA classified
May 6, 2026
FDA report date
April 29, 2026

Other drug recalls from around the same time

Verify with the official sources:

Found something wrong or missing? Report a data error.

Source: U.S. Food & Drug Administration. Agency excerpts come from the public data feed and may omit tables or later changes; the linked government source is authoritative. Source last checked October 22, 2026 at 6:00 PM UTC. Record retrieved July 28, 2026 at 11:00 PM UTC.

Report a data error on this page